Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Jann, M. W. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24, 1759–1783, doi:
10.1592/phco.24.17.1759.52346
(2004).
2. Bridler, R. & Umbricht, D. Atypical antipsychotics in the treatment of schizophrenia. Swiss Med Wkly 133, 63–76, doi:2003/05/smw-10003 (2003).
3. Bou Khalil, R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Clin Neuropharmacol 35, 141–147, doi:
10.1097/WNF.0b013e31824d5288
(2012).
4. Ko, Y. K., Soh, M. A., Kang, S. H. & Lee, J. I. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. Clin Psychopharmacol Neurosci 11, 80–88, doi:
10.9758/cpn.2013.11.2.80
(2013).
5. Said, M. A. et al. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia. Singapore Med J 53, 801–807 (2012).
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献